JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $460
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $445 to $460.
JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $445 to $460.
